Quick Answer
Lantern Pharma Inc. reported Net Income of -$17.12 million for fiscal year 2025.
Lantern Pharma Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$17.12M +17.6% |
-$20.78M -30.2% |
-$15.96M -11.9% |
-$14.26M -15.3% |
-$12.36M -109.3% |
-$5.91M -143.3% |
| Diluted EPS | -$1.57 +18.7% |
-$1.93 -31.3% |
-$1.47 -12.2% |
-$1.31 | — | — |
| Total Assets | $11.04M -56.8% |
$25.57M -41.4% |
$43.65M -25.8% |
$58.84M -20.4% |
$73.95M +263.2% |
$20.36M +1321.2% |
| Cash and Equivalents | $4.42M -41.1% |
$7.51M -65.8% |
$21.94M -41.0% |
$37.20M -27.8% |
$51.52M +167.9% |
$19.23M +1460.8% |
| Stockholders Equity | $6.53M -69.2% |
$21.19M -48.2% |
$40.91M -27.0% |
$56.04M -21.7% |
$71.57M +263.3% |
$19.70M +1988.3% |
| R&D Expense | $11.51M -28.6% |
$16.13M +35.6% |
$11.89M +38.3% |
$8.60M +13.6% |
$7.57M +237.5% |
$2.24M |
| Operating Income | -$17.98M +19.1% |
-$22.22M -24.3% |
-$17.88M -23.9% |
-$14.43M -14.6% |
-$12.59M | — |
| Shares Outstanding | 11.25M +4.4% |
10.78M +0.6% |
10.72M -1.3% |
10.86M -2.1% |
11.09M +78.3% |
6.22M +214.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.18M | +7.3% | +3.5% |
| Diluted EPS | September 30, 2025 | -$0.39 | +7.1% | +2.5% |
| Total Assets | September 30, 2025 | $13.63M | -55.0% | -21.8% |
| Cash and Equivalents | September 30, 2025 | $8.39M | +3.5% | +38.4% |
| Stockholders Equity | September 30, 2025 | $9.59M | -64.0% | -23.4% |
| R&D Expense | September 30, 2025 | $2.44M | -34.4% | -20.6% |
| Operating Income | September 30, 2025 | -$4.35M | +16.0% | +6.5% |
| Shares Outstanding | September 30, 2025 | 11.04M | +2.4% | +2.4% |
- Lantern Pharma Inc. reported Net Income of -$17.12 million for fiscal year 2025.
- Lantern Pharma Inc. showed an increase of +17.6% in Net Income compared to the prior fiscal year.
- Lantern Pharma Inc. reported Diluted EPS of $1.57 per share (loss) for fiscal year 2025.
- Lantern Pharma Inc. showed an increase of +18.7% in Diluted EPS compared to the prior fiscal year.
- Lantern Pharma Inc. reported Total Assets of $11.04 million for fiscal year 2025.
- Lantern Pharma Inc. showed a decrease of -56.8% in Total Assets compared to the prior fiscal year.
- Lantern Pharma Inc. reported Cash and Equivalents of $4.42 million for fiscal year 2025.
- Lantern Pharma Inc. showed a decrease of -41.1% in Cash and Equivalents compared to the prior fiscal year.
- Lantern Pharma Inc. reported Stockholders Equity of $6.53 million for fiscal year 2025.
- Lantern Pharma Inc. showed a decrease of -69.2% in Stockholders Equity compared to the prior fiscal year.
- Lantern Pharma Inc. reported R&D Expense of $11.51 million for fiscal year 2025.
- Lantern Pharma Inc. showed a decrease of -28.6% in R&D Expense compared to the prior fiscal year.
- Lantern Pharma Inc. reported Operating Income of -$17.98 million for fiscal year 2025.
- Lantern Pharma Inc. showed an increase of +19.1% in Operating Income compared to the prior fiscal year.
- Lantern Pharma Inc. reported Shares Outstanding of 11.25 million shares for fiscal year 2025.
- Lantern Pharma Inc. showed an increase of +4.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: